Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to stop bleeds in rare blood disorder

NCT ID NCT06998524

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants, from infants to adults, will receive either emicizumab or continue their current treatment. The goal is to see if emicizumab reduces the number of bleeds that need medical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE, TYPE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

von Willebrand disease 3

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VON WILLEBRAND DISEASE, TYPE 3

Contacts and locations

Locations

  • AOU Careggi

    RECRUITING

    Florence, Tuscany, 50134, Italy

  • Charlotte Maxeke Johannesburg Academic Hospital

    RECRUITING

    Johannesburg, 2193, South Africa

  • Erasmus MC

    RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz

    RECRUITING

    Duisburg, 47051, Germany

  • Great Ormond Street Hospital

    RECRUITING

    London, WC1N 3JH, United Kingdom

  • Groupe Hospitalier Necker Enfants Malades

    RECRUITING

    Paris, 75015, France

  • Hopital Claude Huriez - CHU Lille

    RECRUITING

    Lille, 59037, France

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, 41013, Spain

  • Hospital Universitario la Paz

    RECRUITING

    Madrid, 28046, Spain

  • Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin

    RECRUITING

    Frankfurt/M., 60590, Germany

  • IPS SURA Industriales Medellín

    RECRUITING

    Medellín, Colombia

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico

    RECRUITING

    Milan, Lombardy, 20122, Italy

  • Instytut Hematologii i Transfuzjologii

    RECRUITING

    Warsaw, 02-776, Poland

  • Kurume University Hospital

    RECRUITING

    Fukuoka, 830-0011, Japan

  • Manchester Royal Infirmary

    RECRUITING

    Manchester, M13 9WL, United Kingdom

  • McGill University Health Center

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Nagoya University Hospital

    RECRUITING

    Nagoya, 466-8560, Japan

  • Sahlgrenska Universitetssjukhuset

    RECRUITING

    Gothenburg, S-413 45, Sweden

  • St Thomas' Hospital

    RECRUITING

    London, SE1 7EH, United Kingdom

  • The Hospital for Sick Children

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • UC Davis

    RECRUITING

    Sacramento, California, 95817, United States

  • UZ Leuven Gasthuisberg

    RECRUITING

    Leuven, 3000, Belgium

  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia

    RECRUITING

    Rome, Lazio, 00161, Italy

  • University of Florida

    RECRUITING

    Gainesville, Florida, 32610, United States

  • University of Minnesota Medical Center

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Universitätsklinikum Bonn

    RECRUITING

    Bonn, 53127, Germany

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298-0461, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.